Menu

Science vs. Religion?

Two thirds of religious Americans say there is no conflict between their own beliefs and science, according to a survey from the Pew Research Center.

Oct 26, 2015
Bob Grant

Detail of "Old Woman in Prayer," by Nicolaes MaesWIKIMEDIA, WWW.RIJKSMUSEUM.NLThe rift between science and religion may not be as bad as we thought, at least among people who identify as holding religious beliefs, if a new survey from the Pew Research Center is to be believed. According to the study, which recorded responses from more than 2,000 people, nonreligious people overwhelmingly see science and religion as conflicting world views. “The people who are farther away from religion themselves tend to see stronger conflict, because they’re not as close to actual religious people,” Robert Jones, chief executive of the nonprofit Public Religion Research Institute, told Slate. “They aren’t seeing all those people who don’t have a conflict.”

There is, however, a lot of nuance buried in the survey’s results. Here are some interesting numbers from the analysis: overall, 59 percent of respondents said that science and religion are generally “often in conflict,” while 38 percent said the two were “mostly compatible.” But when asked if science sometimes conflicts with their own religious beliefs, 68 percent of respondents answered that it does not, and 30 percent said that it does conflict. Among that 59 percent who said science and religion are often in conflict, their levels of religious observance modulated their responses to the question. Only 50 percent of people who attend religious services at least weekly said that science and religion are often in conflict, while 73 percent of people who seldom or never attend religious services found conflict. “It is the least religiously observant Americans who are most likely to perceive conflict between science and religion,” Cary Funk, associate director for research at the Pew Research Center, said in a statement.

Further, religious affiliation and worship service attendance only come into play for a couple of key scientific issues—human evolution and the birth of the universe. People’s religious differences do not seem to play a big role in explaining their positions on other hot-button issues, such as climate change, genetically modified foods, and government investment in science. “People expect to see more difference between religious groups on these science topics,” Funk added. “Maybe there are not as many areas where there’s as large a religious difference as people were assuming.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.